Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis
The soluble urokinase-type plasminogen activator receptor (suPAR) has evolved as a useful biomarker for different entities of chronic liver disease. However, its role in patients with primary sclerosing cholangitis (PSC) is obscure. We analyzed plasma levels of suPAR in 84 patients with PSC and comp...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/9/2479 |
| _version_ | 1797504190776344576 |
|---|---|
| author | Burcin Özdirik Martin Maibier Maria Scherf Jule Marie Nicklaus Josephine Frohme Tobias Puengel Dirk Meyer zum Büschenfelde Frank Tacke Tobias Mueller Michael Sigal |
| author_facet | Burcin Özdirik Martin Maibier Maria Scherf Jule Marie Nicklaus Josephine Frohme Tobias Puengel Dirk Meyer zum Büschenfelde Frank Tacke Tobias Mueller Michael Sigal |
| author_sort | Burcin Özdirik |
| collection | DOAJ |
| description | The soluble urokinase-type plasminogen activator receptor (suPAR) has evolved as a useful biomarker for different entities of chronic liver disease. However, its role in patients with primary sclerosing cholangitis (PSC) is obscure. We analyzed plasma levels of suPAR in 84 patients with PSC and compared them to 68 patients with inflammatory bowel disease (IBD) without PSC and to 40 healthy controls. Results are correlated with clinical records. suPAR concentrations were elevated in patients with PSC compared to patients with IBD only and to healthy controls (<i>p</i> < 0.001). Elevated suPAR levels were associated with the presence of liver cirrhosis (<i>p</i> < 0.001) and signs of portal hypertension (<i>p</i> < 0.001). suPAR revealed a high accuracy for the discrimination of the presence of liver cirrhosis comparable to previously validated noninvasive fibrosis markers (area under the curve (AUC) 0.802 (95%CI: 0.702–0.902)). Further, we demonstrated that suPAR levels may indicate the presence of acute cholangitis episodes (<i>p</i> < 0.001). Finally, despite the high proportion of PSC patients with IBD, presence of IBD and its disease activity did not influence circulating suPAR levels. suPAR represents a previously unrecognized biomarker for diagnosis and liver cirrhosis detection in patients with PSC. However, it does not appear to be confounded by intestinal inflammation in the context of IBD. |
| first_indexed | 2024-03-10T04:01:08Z |
| format | Article |
| id | doaj.art-1b7f7d1d5e1544fba8e99b9893b1e343 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:01:08Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-1b7f7d1d5e1544fba8e99b9893b1e3432023-11-23T08:32:54ZengMDPI AGJournal of Clinical Medicine2077-03832022-04-01119247910.3390/jcm11092479Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing CholangitisBurcin Özdirik0Martin Maibier1Maria Scherf2Jule Marie Nicklaus3Josephine Frohme4Tobias Puengel5Dirk Meyer zum Büschenfelde6Frank Tacke7Tobias Mueller8Michael Sigal9Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyThe soluble urokinase-type plasminogen activator receptor (suPAR) has evolved as a useful biomarker for different entities of chronic liver disease. However, its role in patients with primary sclerosing cholangitis (PSC) is obscure. We analyzed plasma levels of suPAR in 84 patients with PSC and compared them to 68 patients with inflammatory bowel disease (IBD) without PSC and to 40 healthy controls. Results are correlated with clinical records. suPAR concentrations were elevated in patients with PSC compared to patients with IBD only and to healthy controls (<i>p</i> < 0.001). Elevated suPAR levels were associated with the presence of liver cirrhosis (<i>p</i> < 0.001) and signs of portal hypertension (<i>p</i> < 0.001). suPAR revealed a high accuracy for the discrimination of the presence of liver cirrhosis comparable to previously validated noninvasive fibrosis markers (area under the curve (AUC) 0.802 (95%CI: 0.702–0.902)). Further, we demonstrated that suPAR levels may indicate the presence of acute cholangitis episodes (<i>p</i> < 0.001). Finally, despite the high proportion of PSC patients with IBD, presence of IBD and its disease activity did not influence circulating suPAR levels. suPAR represents a previously unrecognized biomarker for diagnosis and liver cirrhosis detection in patients with PSC. However, it does not appear to be confounded by intestinal inflammation in the context of IBD.https://www.mdpi.com/2077-0383/11/9/2479primary sclerosing cholangitisbiomarkerssoluble urokinase plasminogen activator receptorliver cirrhosis |
| spellingShingle | Burcin Özdirik Martin Maibier Maria Scherf Jule Marie Nicklaus Josephine Frohme Tobias Puengel Dirk Meyer zum Büschenfelde Frank Tacke Tobias Mueller Michael Sigal Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis Journal of Clinical Medicine primary sclerosing cholangitis biomarkers soluble urokinase plasminogen activator receptor liver cirrhosis |
| title | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis |
| title_full | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis |
| title_fullStr | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis |
| title_full_unstemmed | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis |
| title_short | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis |
| title_sort | soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in patients with primary sclerosing cholangitis |
| topic | primary sclerosing cholangitis biomarkers soluble urokinase plasminogen activator receptor liver cirrhosis |
| url | https://www.mdpi.com/2077-0383/11/9/2479 |
| work_keys_str_mv | AT burcinozdirik solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT martinmaibier solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT mariascherf solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT julemarienicklaus solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT josephinefrohme solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT tobiaspuengel solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT dirkmeyerzumbuschenfelde solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT franktacke solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT tobiasmueller solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis AT michaelsigal solubleurokinaseplasminogenactivatorreceptorlevelsareassociatedwithseverityoffibrosisinpatientswithprimarysclerosingcholangitis |